1. Home
  2. AHCO vs EWTX Comparison

AHCO vs EWTX Comparison

Compare AHCO & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AHCO
  • EWTX
  • Stock Information
  • Founded
  • AHCO 2012
  • EWTX 2017
  • Country
  • AHCO United States
  • EWTX United States
  • Employees
  • AHCO N/A
  • EWTX N/A
  • Industry
  • AHCO Medical/Nursing Services
  • EWTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • AHCO Health Care
  • EWTX Health Care
  • Exchange
  • AHCO Nasdaq
  • EWTX Nasdaq
  • Market Cap
  • AHCO 1.3B
  • EWTX 1.4B
  • IPO Year
  • AHCO N/A
  • EWTX 2021
  • Fundamental
  • Price
  • AHCO $9.29
  • EWTX $13.71
  • Analyst Decision
  • AHCO Strong Buy
  • EWTX Buy
  • Analyst Count
  • AHCO 5
  • EWTX 9
  • Target Price
  • AHCO $13.40
  • EWTX $39.89
  • AVG Volume (30 Days)
  • AHCO 1.6M
  • EWTX 791.6K
  • Earning Date
  • AHCO 08-05-2025
  • EWTX 08-07-2025
  • Dividend Yield
  • AHCO N/A
  • EWTX N/A
  • EPS Growth
  • AHCO N/A
  • EWTX N/A
  • EPS
  • AHCO 0.58
  • EWTX N/A
  • Revenue
  • AHCO $3,246,360,000.00
  • EWTX N/A
  • Revenue This Year
  • AHCO $1.72
  • EWTX N/A
  • Revenue Next Year
  • AHCO $4.52
  • EWTX N/A
  • P/E Ratio
  • AHCO $15.95
  • EWTX N/A
  • Revenue Growth
  • AHCO N/A
  • EWTX N/A
  • 52 Week Low
  • AHCO $7.11
  • EWTX $10.60
  • 52 Week High
  • AHCO $11.90
  • EWTX $38.12
  • Technical
  • Relative Strength Index (RSI)
  • AHCO 53.23
  • EWTX 47.19
  • Support Level
  • AHCO $9.11
  • EWTX $12.51
  • Resistance Level
  • AHCO $9.63
  • EWTX $14.30
  • Average True Range (ATR)
  • AHCO 0.39
  • EWTX 0.67
  • MACD
  • AHCO 0.02
  • EWTX 0.06
  • Stochastic Oscillator
  • AHCO 74.84
  • EWTX 58.15

About AHCO AdaptHealth Corp.

AdaptHealth Corp is engaged in providing patient-centered, healthcare-at-home solutions including home medical equipment (HME), medical supplies, and related services. It focuses on providing; sleep therapy equipment, supplies, and related services (including CPAP and bi-PAP services) to individuals suffering from obstructive sleep apnea (OSA), medical devices and supplies to patients for the treatment of diabetes (including continuous glucose monitors (CGM and insulin pumps), home medical equipment to patients discharged from acute care and other facilities, oxygen and related chronic therapy services in the home, and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy and nutritional supply needs.

About EWTX Edgewise Therapeutics Inc.

Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.

Share on Social Networks: